Mark J. Hamblin

Mark J. Hamblin

Pulmonary Medicine
2000 Olathe Boulevard
Kansas City, KS 66160

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Reply to Sun et al.: Interpreting Benefit in ELEVATE-IPF.

Reply to Sun et al.: Interpreting Benefit in ELEVATE-IPF.

Journal: American journal of respiratory and critical care medicine
Published: April 21, 2026

Reply to Sun et al.: Interpreting benefit in ELEVATE-IPF.

Reply to Sun et al.: Interpreting benefit in ELEVATE-IPF.

Journal: American journal of respiratory and critical care medicine
Published: April 21, 2026

Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial.

Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial.

Journal: American journal of respiratory and critical care medicine
Published: December 12, 2025

Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial.

Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial.

Journal: American journal of respiratory and critical care medicine
Published: December 12, 2025

Circulating Extracellular Vesicle miRNA Signatures in Interstitial Lung Disease.

Circulating Extracellular Vesicle miRNA Signatures in Interstitial Lung Disease.

Journal: American journal of respiratory cell and molecular biology
Published: October 08, 2025

Role of Radiographic Fibrosis Extent in Identifying Immunomodulatory Treatment Response in Hypersensitivity Pneumonitis.

Role of Radiographic Fibrosis Extent in Identifying Immunomodulatory Treatment Response in Hypersensitivity Pneumonitis.

Journal: Chest
Published: September 08, 2025

Characterization of Pulmonary Functional Abnormalities in Systemic Sclerosis Using Xenon MRI.

Characterization of Pulmonary Functional Abnormalities in Systemic Sclerosis Using Xenon MRI.

Journal: Journal of magnetic resonance imaging : JMRI
Published: August 01, 2025

Effect of Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist, on Disease Progression in Pulmonary Fibrosis.

Effect of Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist, on Disease Progression in Pulmonary Fibrosis.

Journal: Chest
Published: December 12, 2024

Hypersensitivity Pneumonitis: Updates in Evaluation, Management, and Ongoing Dilemmas.

Hypersensitivity Pneumonitis: Updates in Evaluation, Management, and Ongoing Dilemmas.

Journal: Immunology and allergy clinics of North America
Published: April 13, 2023

A Phase IIb Randomized Clinical Study of an Anti-αvβ6 Monoclonal Antibody in Idiopathic Pulmonary Fibrosis.

A Phase IIb Randomized Clinical Study of an Anti-αvβ6 Monoclonal Antibody in Idiopathic Pulmonary Fibrosis.

Journal: American journal of respiratory and critical care medicine
Published: June 30, 2022

Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study.

Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study.

Journal: Respiratory research
Published: December 06, 2021

Diagnosis, course and management of hypersensitivity pneumonitis.

Diagnosis, course and management of hypersensitivity pneumonitis.

Journal: European respiratory review : an official journal of the European Respiratory Society
Published: July 13, 2021
Showing 1-12 of 22

Last Updated: 09/26/2026